Clinical Trial Update: Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bendamustine with rituximab, with or without bortezomib, followed by rituximab with or without lenalidomide in high-risk follicular lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Bendamustine Hydrochloride (bendamustine)
• Bortezomib (bortezomib)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2021-02-23